AI English summary of an SEC filing — figures as filed

The company said revenue for Q3 2025 grew 5% to $11.12 billion. It said GAAP diluted EPS was $4.27 and adjusted EPS was $5.79 (versus $5.28 in the year-ago period). Organic revenue growth was 3%.

8-KResults of Operations and Financial ConditionFiled Oct 22, 2025Period of report Oct 22, 2025Summary published (UTC) Oct 7, 2026

Key points

AI summary

The company said revenue for Q3 2025 grew 5% to $11.12 billion. It said GAAP diluted EPS was $4.27 and adjusted EPS was $5.79 (versus $5.28 in the year-ago period). Organic revenue growth was 3%.
The company said GAAP operating income for Q3 was $1.94 billion (operating margin of 17.4%, versus 17.3% a year earlier), and adjusted operating income was $2.59 billion (adjusted operating margin of 23.3%, versus 22.3% a year earlier).
Thermo Fisher said operating cash flow for Q3 was $2,239 million, and free cash flow (non-GAAP) was $1,840 million ($1,915 million in the prior-year period). Free cash flow for the 9 months to date was $3,319 million ($4,498 million a year earlier).
Thermo Fisher said it completed its acquisitions of Solventum's Filtration and Separation business and Sanofi's Ridgefield, New Jersey sterile fill-finish site in Q3, and repurchased $1.0 billion of its stock.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Thermo Fisher Q3 Revenue $11.12 billion, Adjusted EPS $5.79

The company said revenue for Q3 2025 grew 5% to $11.12 billion. It said GAAP diluted EPS was $4.27 and adjusted EPS was $5.79 (versus $5.28 in the year-ago period). Organic revenue growth was 3%.

Source · Based on the filing body and exhibits

Thermo Fisher Q3 Operating Margin GAAP 17.4%, Adjusted 23.3%

The company said GAAP operating income for Q3 was $1.94 billion (operating margin of 17.4%, versus 17.3% a year earlier), and adjusted operating income was $2.59 billion (adjusted operating margin of 23.3%, versus 22.3% a year earlier).

Source · Based on the filing body and exhibits

Thermo Fisher Q3 and 9-Month Free Cash Flow

Thermo Fisher said operating cash flow for Q3 was $2,239 million, and free cash flow (non-GAAP) was $1,840 million ($1,915 million in the prior-year period). Free cash flow for the 9 months to date was $3,319 million ($4,498 million a year earlier).

Source · Based on the filing body and exhibits

Thermo Fisher Completes Acquisitions in Q3 and Repurchases $1.0 billion of Stock

Thermo Fisher said it completed its acquisitions of Solventum's Filtration and Separation business and Sanofi's Ridgefield, New Jersey sterile fill-finish site in Q3, and repurchased $1.0 billion of its stock.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.